AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03437031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality device
Description: For those patients randomized to VR, the study staff member will explain the use of the Samsung VR goggle set, and thereafter will allow the patient to use the device freely for up to 30 minutes. Intervals of 2-5 minutes is suggested for first-time use, and patients will be to allowed to discontinue it at any time as long as they are not experiencing any discomfort or side effects (dizziness, motion sickness, etc.). The study staff member will be present at all times, and will work with hospital staff as necessary to ensure the patient is receiving appropriate clinical care throughout the duration of the intervention.
Study NCT03229135 — intervention group
Intervention type: DEVICE
Intervention: other antibacterial agents，breathing machine
Description: If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
Study NCT03078647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound
Description: The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
Study NCT03516513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy as Usual
Description: Treatment as usual to deliver 6 weekly sessions to teach patients how to use the seven step process to solve problems.
Study NCT03516513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted Problem Solving Therapy
Description: Smart note assisted delivery of 6 weekly session to teach patients how to use the seven step process to solve problems
Study NCT05805982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Pre-recorded educational video including hereditary cancer information, genetic cancer testing candidates, types of testing, type of results, benefits and risks, recommendations according to results, inheritance and common questions.
Study NCT04223375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Training
Description: Postpartum women were educated on postpartum healthy and regular nutrition.
Study NCT04128501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC
Study NCT04128501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT01307748 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aroma
Description: Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
Study NCT05805982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In person genetic cancer counseling
Description: Includes:~Family history of cancer (3-generation family tree) Personal Cancer Risk Assessment Education on inheritance and expression of disease Types of tests Preparation on possible outcomes according to results Obtaining consent for test Opportunity to solve doubts
Study NCT01307748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aroma
Description: Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
Study NCT02286258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium EDTA
Description: Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR
Study NCT02286258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gd-DOTA
Description: Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR
Study NCT02441660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% Patch
Description: Applied topically for 1 hour
Study NCT02441660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Capsaicin 0.025% Well Patch
Study NCT03173599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 40mg
Description: The beginning dose is 40mg.
Study NCT03173599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 80mg
Description: The single dose is 80mg.
Study NCT03173599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 160mg
Description: The single dose is 160mg.
Study NCT03173599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 240mg
Description: The single dose is 240mg.
Study NCT03173599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 360mg
Description: The single dose is 360mg.
Study NCT03173599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA 480mg
Description: The single dose is 480mg.
Study NCT03173599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PNA Placebo
Description: The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
Study NCT01454869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
Study NCT01454869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
Study NCT01116297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging with S-FLARE imaging system
Description: Tissue oxygenation measurements during plastic surgery using the S-FLARE system.
Study NCT03035708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 1 mg BID
Study NCT03035708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1 mg BID
Study NCT01199523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01199523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study NCT01199523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: oral
Study NCT00795756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposome-encapsulated cytarabine (DepoCyte)
Description: DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
Study NCT00795756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple intrathecal therapy (TIT)
Description: Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
Study NCT03084874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and sedentary behavior coaching program
Description: The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
Study NCT01928329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide (Bydureon®)
Study NCT01928329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01637467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Description: EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
Study NCT01637467 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham EMS
Description: Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
Study NCT01065233 — intervention group
Intervention type: GENETIC
Intervention: DNA extraction
Description: DNA extraction of blood sample for DNAship analysis
Study NCT03611790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeVa VS
Description: mechanical dilatation
Study NCT02136186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips Telehealth
Description: patients will be provided with a philips home telemonitoring system post hospital discharge
Study NCT00697203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 12 weeks
Study NCT00697203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 40mg po daily for 12 weeks
Study NCT00697203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pravastatin
Description: 40mg po daily for 12 weeks
Study NCT00697203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Description: 300mg po daily for 12 weeks
Study NCT00697203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Description: 600mg po daily for 12 weeks
Study NCT01240785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
Study NCT01240785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
Study NCT00258115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: salsalate
Study NCT00258115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salsalate
Study NCT03172975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel
Description: Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
Study NCT03172975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel + CPG 10104
Description: Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
Study NCT03172975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel + GLA-AF
Description: Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
Study NCT03172975 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological sterile saline solution
Study NCT03172975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
Study NCT02770872 — intervention group
Intervention type: OTHER
Intervention: Observation of SAA on apoB containing lipoproteins
Description: attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
Study NCT02678702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: CBT-I
Study NCT02678702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual
Study NCT02678702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual
Study NCT02423733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Journal
Description: The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care.
Study NCT03704428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
Study NCT00644033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frovatriptan
Description: 2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
Study NCT00644033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frovatriptan
Description: 2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
Study NCT00644033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
Study NCT04184466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: insulin aspart in doses 0.3 IU/kg
Study NCT04184466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid® Penfill®
Description: insulin aspart in doses 0.3 IU/kg
Study NCT02773849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSTILADRIN
Study NCT01547208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate radiofrequency ablation of ventricular tachycardia
Description: Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
Study NCT01547208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation of ventricular tachycardia
Description: Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
Study NCT05155540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trevo and or Merci devices for stent retreival
Description: FDA approved devices for stent retrieval during mechanical thrombectomy
Study NCT00697203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Description: 900mg po daily for 12 weeks
Study NCT03893422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-010
Description: Medical food formulation
Study NCT03893422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-011
Description: WB-011 medical food product
Study NCT03893422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules identical to those containing WB-010 and WB-011.
Study NCT03863990 — intervention group
Intervention type: DRUG
Intervention: PAH medication
Description: Any PAH-targeted medication
Study NCT00255047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAPTACEL®. (DTaP), IPOL®., and ActHIB®.
Description: 0.5 mL, Intramuscular
Study NCT05155540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penumbra system for stent aspiration
Description: FDA approved devices for stent aspiration during mechanical thrombectomy
Study NCT05155540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant tissue plasminogen activator
Description: FDA approved drug for treatment of acute ischemic stroke within 4.5 hours of strokeonset
Study NCT00255047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel®: DTaP-IPV/Hib combined
Description: 0.5 mL, Intramuscular
Study NCT00255047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV and ActHIB®
Description: 0.5 mL, Intramuscular
Study NCT03092531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive STEPS
Description: Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.
Study NCT01163487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Description: 25-50mg/kg per day; oral
Study NCT01163487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EF5
Description: 21 mg/kg; IV
Study NCT02103504 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy Attune posterior stabilized fixed bearing total knee replacement
Study NCT02290223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Based Treatment Model
Description: Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
Study NCT04326348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105
Description: TQ05105 is a JAK2 inhibitor.
Study NCT03064191 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: calcium hydroxide chlorhexidine combination
Description: Endodontic intra-canal medicament used for decreasing postoperative signs ans symptoms
Study NCT03064191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: calcium hydroxide intra-canal medicament
Description: Endodontic intra-canal medicament used for decreasing postoperative signs and symptoms.
Study NCT03350633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injection
Description: Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.
Study NCT03350633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine will be orally given at a dose of 2-3 mg/kg/d
Study NCT01981291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraneural Injection for Subgluteal Sciatic Nerve Block
Description: The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.
Study NCT01981291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural Injection for Subgluteal Sciatic Nerve Block
Description: The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.
Study NCT01981291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
Study NCT01981291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
Study NCT01981291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled postoperative analgesia
Description: Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
Study NCT01981291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled postoperative analgesia
Description: Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
Study NCT01981291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
Study NCT01981291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
Study NCT01333059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT02117973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iAssist Technique using Persona system vs. the conventional technique using Persona system
Study NCT02117973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iAssist Technique using Persona system vs. the conventional technique using Persona system
Study NCT01333059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT01333059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline